An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone Oxycodone Controlled Release (CR) and/or Morphine Sustained Release (SR)

The purpose of this study is to evaluate tapentadol Extended Release (ER) in the treatment
of moderate to severe chronic pain in participants with a diagnosis of chronic low back pain
(LBP) or osteoarthritis (OA) of the hip or knee after conversion from hydrocodone, oxycodone
Controlled Release (CR), and/or morphine Sustained Release (SR).

Clinical Trial Conditions: Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee

Treatments in this Clinical Trial : Nucynta ER

Clinical Trial Phase: Phase 4

Eligible Clinical Trial Participant Age : Between 18 years to 74 years

Can Healthy Volunteers Participate: No

Clinical Trial Lead Sponsor: Janssen Scientific Affairs, LLC

Detailed Clinical Trial Description: The purpose of this study is to evaluate tapentadol Extended Release (ER) in the treatment
of moderate to severe chronic pain in participants with a diagnosis of chronic low back pain
(LBP) or osteoarthritis (OA) of the hip or knee after conversion from hydrocodone, oxycodone
Controlled Release (CR), and/or morphine Sustained Release (SR).

The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01631513